AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30895881 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 157
Study 28687934 — intervention group
Group type: EXPERIMENTAL
Intervention: KGB and AG (6 g of fibre from KGB and 3 g of AG)
Number of subjects: 39
Study 28687934 — intervention group
Group type: EXPERIMENTAL
Intervention: KGB and AG
Number of subjects: 39
Study 28687934 — intervention group
Group type: COMPARATOR
Intervention: Control (wheat bran-based, fibre-matched)
Number of subjects: 39
Study 26990198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced sonification
Number of subjects: 76
Study 26990198 — intervention group
Group type: COMPARATOR
Intervention: Conventional sonification
Number of subjects: 76
Study 25129881 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + H (Homeopathy)
Number of subjects: 50
Study 25129881 — intervention group
Group type: COMPARATOR
Intervention: SRP (Control Group)
Number of subjects: 50
Study 22232563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg bevacizumab
Number of subjects: 24
Study 22232563 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 24
Study 19605879 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus oral health education
Number of subjects: 60
Study 19605879 — intervention group
Group type: COMPARATOR
Intervention: Oral health education alone
Number of subjects: 60
Study 17238881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg x kg(‐1)
Number of subjects: 181
Study 14618287 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (electromyographically triggered neuromuscular electrical stimulation)
Number of subjects: 16
Study 14618287 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16
Study 14618287 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 16
Study 11240084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 134
Study 11240084 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate immediate release (MSIR)
Number of subjects: 134
Study 11240084 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC
Number of subjects: 134
Study 9712233 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients
Number of subjects: 80
Study 9712233 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative patients
Number of subjects: 80
Study 7521041 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 0
Study 7521041 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 0
Study 3044869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg/day
Number of subjects: 0
Study 3044869 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 0
Study 3044869 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 3044869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 31181244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS with rTMS (tDCS-rTMS)
Number of subjects: 11
Study 31181244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (sham rTMS)
Number of subjects: 11
Study 31181244 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (sham tDCS)
Number of subjects: 11
Study 31181244 — intervention group
Group type: COMPARATOR
Intervention: Sham control (no tDCS or rTMS)
Number of subjects: 11
Study 28232973 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral health intervention (spoken)
Number of subjects: 175
Study 28232973 — intervention group
Group type: EXPERIMENTAL
Intervention: Written intervention
Number of subjects: 175
Study 28232973 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 175
Study 26390092 — intervention group
Group type: COMPARATOR
Intervention: rAAV9-DES-hGAA injected intramuscularly into the tibialis anterior muscle
Number of subjects: 6
Study 26390092 — intervention group
Group type: COMPARATOR
Intervention: Control injection of excipient dosing in the contralateral leg
Number of subjects: 6
Study 23499204 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G sodium and gentamicin
Number of subjects: 200
Study 23499204 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and amikacin
Number of subjects: 200
Study 23499204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 200
Study 21135704 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (4 sachets of 2.5 billion bacteria per sachet for 7 days)
Number of subjects: 50
Study 21135704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 sachets for 7 days)
Number of subjects: 50
Study 19353264 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Mixed‐Methods Participatory Evaluation (CMMPE) model
Number of subjects: 0
Study 19353264 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention
Number of subjects: 0
Study 17088514 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct tape
Number of subjects: 103
Study 17088514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 14681343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystal budesonide 0.5 mg
Number of subjects: 16
Study 14681343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystal budesonide 1.0 mg
Number of subjects: 16
Study 14681343 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Respules 0.5 mg
Number of subjects: 16
Study 14681343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11265932 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐Dk soft contact lenses
Number of subjects: 32
Study 11265932 — intervention group
Group type: COMPARATOR
Intervention: Non-contact lens wearers
Number of subjects: 32
Study 9313712 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB testing and flexible sigmoidoscopy (FOS)
Number of subjects: 6371
Study 9313712 — intervention group
Group type: COMPARATOR
Intervention: FOB testing alone
Number of subjects: 6371
Study 8395476 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy lunch (985 kcal)
Number of subjects: 12
Study 8395476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy lunch (527 kcal)
Number of subjects: 12
Study 8395476 — intervention group
Group type: COMPARATOR
Intervention: High CHO dinner meal
Number of subjects: 12
Study 8395476 — intervention group
Group type: COMPARATOR
Intervention: High fat dinner meal
Number of subjects: 12
Study 8395476 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy lunch (985 kcal) with high fat dinner
Number of subjects: 12
Study 8395476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy lunch (527 kcal) with high CHO dinner
Number of subjects: 12
Study 3513080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine/pyrilamine eyedrops (combination treatment)
Number of subjects: 18
Study 3513080 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine eyedrops (alone)
Number of subjects: 18
Study 3513080 — intervention group
Group type: COMPARATOR
Intervention: Pyrilamine eyedrops (alone)
Number of subjects: 18
Study 3513080 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 18
Study 29848153 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 269
Study 29848153 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 269
Study 29848153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 269
Study 29848153 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 269
Study 29848153 — intervention group
Group type: EXPERIMENTAL
Intervention: All biologics
Number of subjects: 269
Study 30241509 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior minimally-invasive (AMIS) approach
Number of subjects: 190
Study 30241509 — intervention group
Group type: COMPARATOR
Intervention: Lateral Hardinge (LAT) approach
Number of subjects: 190
Study 30241509 — intervention group
Group type: EXPERIMENTAL
Intervention: AMIS group
Number of subjects: 190
Study 25647283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondipper Hypertension (NDHT)
Number of subjects: 77
Study 25647283 — intervention group
Group type: COMPARATOR
Intervention: Dipper Hypertension (DHT)
Number of subjects: 77
Study 25028536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystal formulation of megestrol acetate (625 mg/5 mL) in fasting state
Number of subjects: 93
Study 25028536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystal formulation of megestrol acetate (625 mg/5 mL) in fed state
Number of subjects: 93
Study 25028536 — intervention group
Group type: COMPARATOR
Intervention: Megace OS (800 mg/20 mL) in fasting state
Number of subjects: 93
Study 25028536 — intervention group
Group type: COMPARATOR
Intervention: Megace OS (800 mg/20 mL) in fed state
Number of subjects: 93
Study 22930542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention care (multidisciplinary intervention including screening questionnaire, education, pain medication management, physiotherapy-guided exercise, communication with primary care physician)
Number of subjects: 139
Study 22930542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention care
Number of subjects: 139
Study 22930542 — intervention group
Group type: COMPARATOR
Intervention: Usual care (educational pamphlet)
Number of subjects: 139
Study 19208609 — intervention group
Group type: EXPERIMENTAL
Intervention: Online module
Number of subjects: 99
Study 19208609 — intervention group
Group type: COMPARATOR
Intervention: Textbook group
Number of subjects: 99
Study 19208609 — intervention group
Group type: COMPARATOR
Intervention: Tutor-led group
Number of subjects: 99
Study 19088619 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 57
Study 19088619 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 57
Study 15375809 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat wrap therapy
Number of subjects: 93
Study 15375809 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 93
Study 11277448 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral informative cueing
Number of subjects: 0
Study 11277448 — intervention group
Group type: EXPERIMENTAL
Intervention: Central informative cueing
Number of subjects: 0
Study 11277448 — intervention group
Group type: COMPARATOR
Intervention: Peripheral uninformative cueing
Number of subjects: 0
Study 7978433 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 0: immediately turned supine after spinal injection
Number of subjects: 60
Study 7978433 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 6: 6 min in lateral decubitus then supine
Number of subjects: 60
Study 7978433 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 12: 12 min in lateral decubitus then supine
Number of subjects: 60
Study 7978433 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 18: 18 min in lateral decubitus then supine
Number of subjects: 60
Study 2568061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water iontophoresis
Number of subjects: 11
Study 2568061 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment every second week
Number of subjects: 11
Study 2568061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31155871 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire-needling plus stuck-needle-stretching
Number of subjects: 60
Study 31155871 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study 29034648 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia CD
Number of subjects: 120
Study 29034648 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 120
Study 26539769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy
Number of subjects: 2940
Study 26539769 — intervention group
Group type: COMPARATOR
Intervention: Basic dissemination strategy
Number of subjects: 2940
Study 26539769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy with nine or more Go Sun Smart materials
Number of subjects: 2940
Study 26539769 — intervention group
Group type: COMPARATOR
Intervention: Basic dissemination strategy with fewer than nine Go Sun Smart materials
Number of subjects: 2940
Study 23443764 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload with gelofusine at 10 ml·kg(‐1)·h(‐1)
Number of subjects: 45
Study 23443764 — intervention group
Group type: COMPARATOR
Intervention: Colloid preload with gelofusine at 5 ml·kg(‐1)·h(‐1)
Number of subjects: 45
Study 23443764 — intervention group
Group type: COMPARATOR
Intervention: Colloid preload with gelofusine at 15 ml·kg(‐1)·h(‐1)
Number of subjects: 45
Study 21398038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg twice daily to a maximum of 300 mg twice daily for 28 days)
Number of subjects: 0
Study 21398038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 21398038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20193529 — intervention group
Group type: EXPERIMENTAL
Intervention: batroxobin
Number of subjects: 127
Study 20193529 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 127
Study 20193529 — intervention group
Group type: EXPERIMENTAL
Intervention: batroxobin and LMWH
Number of subjects: 127
Study 20193529 — intervention group
Group type: EXPERIMENTAL
Intervention: urokinase and LMWH
Number of subjects: 127
Study 20193529 — intervention group
Group type: EXPERIMENTAL
Intervention: micro pump administration of batroxobin
Number of subjects: 127
Study 16960923 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab 5 mg/kg
Number of subjects: 200
Study 16960923 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study 12742333 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery Doppler examination and 100 mg aspirin daily from Doppler examination through 36 weeks
Number of subjects: 1853
Study 12742333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1853
Study 12742333 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal Doppler findings
Number of subjects: 1853
Study 10683348 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9641
Study 10683348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9641
Study 10683348 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 9641
Study 9146853 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (20-160 ng kg-1 min-1)
Number of subjects: 32
Study 9146853 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion with ganglionic blockade (trimetaphan)
Number of subjects: 32
Study 9146853 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenaline levels
Number of subjects: 32
Study 7639380 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 2 cm H2O (Group I)
Number of subjects: 20
Study 7639380 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 5 cm H2O (Group II)
Number of subjects: 20
Study 7639380 — intervention group
Group type: COMPARATOR
Intervention: Two-lung ventilation (control)
Number of subjects: 20
Study 3218950 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTC) 10 mg IV
Number of subjects: 14
Study 3218950 — intervention group
Group type: EXPERIMENTAL
Intervention: Metopimazine (MTP) 10 mg IV
Number of subjects: 14
Study 3218950 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 subjects)
Number of subjects: 14
Study 31778823 — intervention group
Group type: EXPERIMENTAL
Intervention: GB001 5 mg
Number of subjects: 158
Study 31778823 — intervention group
Group type: EXPERIMENTAL
Intervention: GB001 20 mg
Number of subjects: 158
Study 31778823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 29126161 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 6864
Study 29126161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6864
Study 29126161 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 6864
Study 26630400 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR alone
Number of subjects: 32
Study 26630400 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + IVR combined treatment
Number of subjects: 32
Study 26630400 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 32
Study 26149717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1861
Study 26149717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1861
Study 26149717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1861
Study 23388385 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) referral system
Number of subjects: 2423
Study 23388385 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW referral system
Number of subjects: 2423
Study 22088040 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination of sounds obeying the correlation
Number of subjects: 0
Study 22088040 — intervention group
Group type: COMPARATOR
Intervention: Discrimination of sounds violating the correlation
Number of subjects: 0
Study 18782641 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 295
Study 18782641 — intervention group
Group type: COMPARATOR
Intervention: Exenatide twice daily (10 µg)
Number of subjects: 295
Study 18782641 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 295
Study 18782641 — intervention group
Group type: COMPARATOR
Intervention: Exenatide twice daily
Number of subjects: 295
Study 16289254 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Italian Cognitive Questionnaire (BICQ)
Number of subjects: 963
Study 14738210 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAPs) exposure (200 microg/m3) for 2 hours
Number of subjects: 24
Study 14738210 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 24
Study 11776072 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 785
Study 11776072 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTX‐A
Number of subjects: 785
Study 9196108 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (flow assist = 2 cm H2O/L/s plus volume assist = 4 cm H2O/L)
Number of subjects: 13
Study 9196108 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation
Number of subjects: 13
Study 8485793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg sublingually 20 min before induction of anaesthesia
Number of subjects: 30
Study 8485793 — intervention group
Group type: COMPARATOR
Intervention: Placebo sublingually 20 min before induction of anaesthesia
Number of subjects: 30
Study 3688160 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate scarcity (two essential tools per three subjects)
Number of subjects: 36
Study 3688160 — intervention group
Group type: EXPERIMENTAL
Intervention: High scarcity (one essential tool per three subjects)
Number of subjects: 36
Study 3688160 — intervention group
Group type: EXPERIMENTAL
Intervention: No scarcity (three essential tools per three subjects)
Number of subjects: 36
Study 29260907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (4400 lx)
Number of subjects: 26
Study 29260907 — intervention group
Group type: COMPARATOR
Intervention: Control light (230 lx)
Number of subjects: 26
Study 26773108 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 107
Study 26773108 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 107
Study 26773108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 24014134 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily
Number of subjects: 43
Study 24014134 — intervention group
Group type: COMPARATOR
Intervention: Control group (ongoing antidiabetic therapy)
Number of subjects: 43
Study 22218402 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cessation with nicotine patch therapy (2 weeks)
Number of subjects: 0
Study 22218402 — intervention group
Group type: COMPARATOR
Intervention: Reduction approach with either 4 mg nicotine lozenge or ST brand switching
Number of subjects: 0
Study 19854555 — intervention group
Group type: EXPERIMENTAL
Intervention: Arctic Sun
Number of subjects: 64
Study 19854555 — intervention group
Group type: COMPARATOR
Intervention: Standard cooling (blankets and ice packs)
Number of subjects: 64
Study 18235213 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole 2 g/8 h i.v. (n = 8)
Number of subjects: 16
Study 18235213 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg/4 h s.c. (n = 8)
Number of subjects: 16
Study 15905654 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (GPR method strengthening and flexibility exercises)
Number of subjects: 45
Study 15905654 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional physical therapy protocol)
Number of subjects: 45
Study 15905654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergroup comparison
Number of subjects: 45
Study 14608143 — intervention group
Group type: EXPERIMENTAL
Intervention: poly‐N‐acetylglucosamine (pGlcNAc)
Number of subjects: 0
Study 10663966 — intervention group
Group type: EXPERIMENTAL
Intervention: Kainic acid (KA) administration
Number of subjects: 2
Study 8781194 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate (CHO) drink (CI)
Number of subjects: 17
Study 8781194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PI)
Number of subjects: 17
Study 1464075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg methyl prednisolone (three pulses)
Number of subjects: 34